StreetInsider.com News Articles

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: Del Giudice Matthew Paul

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543346.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: Del Giudice Matthew Paul

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543346.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: MacPherson Edward Clouston

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543351.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: MacPherson Edward Clouston

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543351.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: Aminov Erez

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543352.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: Aminov Erez

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543352.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: Whalen Matthew Pratt

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543353.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: Whalen Matthew Pratt

Fri, 22 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260522/26543353.html

Form 8-K Telomir Pharmaceuticals, For: May 20

Wed, 20 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260520/26525136.html

Form 8-K Telomir Pharmaceuticals, For: May 20

Wed, 20 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260520/26525136.html

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Wed, 20 May 2026 08:00:00 -0400

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease Model.

MIAMI, FL / ACCESS Newswire / May 20, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson's disease model, supporting the biological activity of Telomir-Zn

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Wed, 20 May 2026 08:00:00 -0400

Form 10-Q Telomir Pharmaceuticals, For: Mar 31

Thu, 14 May 2026 15:10:00 -0400

si-local-file:///var/storage/secattach/20260514/26493936.html

Form 10-Q Telomir Pharmaceuticals, For: Mar 31

Thu, 14 May 2026 15:10:00 -0400

si-local-file:///var/storage/secattach/20260514/26493936.html

Telomir receives FDA clearance for cancer drug trial

Thu, 30 Apr 2026 08:50:24 -0400

Telomir Pharmaceuticals Inc. (NASDAQ: TELO) announced that the Food and Drug Administration cleared its Investigational New Drug application for Telomir-Zn, enabling clinical trials for treating advanced or metastatic triple-negative breast cancer.

The Miami-based biotechnology company plans to initiate a first-in-human Phase 1/2 trial in the first half of 2026, anchored by a U.S. academic medical center. The study will enroll approximately 76 adult patients with advanced or metastatic triple-negative breast cancer who have received prior systemic therapy.

The planned trial includes two phases. Phase 1 will use a modified 3+3 dose-escalation design to evaluate safety, tolerability and dose-limiting toxicities while determining the

Form 8-K Telomir Pharmaceuticals, For: Apr 24

Thu, 30 Apr 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20260430/26401323.html

Form 8-K Telomir Pharmaceuticals, For: Apr 24

Thu, 30 Apr 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20260430/26401323.html

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Thu, 30 Apr 2026 08:00:00 -0400

Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center.

MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC).

This IND

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Thu, 30 Apr 2026 08:00:00 -0400

Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center.

This IND

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Form 4 Telomir Pharmaceuticals, For: Apr 22 Filed by: Aminov Erez

Fri, 24 Apr 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260424/26365881.html

Form 4 Telomir Pharmaceuticals, For: Apr 22 Filed by: Aminov Erez

Fri, 24 Apr 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260424/26365881.html

Telomir Pharmaceuticals completes TELI acquisition for global drug rights

Fri, 24 Apr 2026 09:00:37 -0400

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) announced the completion of its acquisition of TELI Pharmaceuticals, Inc., securing worldwide rights to its lead drug candidate Telomir-1.

The stock-for-stock transaction was approved by Telomir shareholders at the company's annual meeting on March 23. Prior to the acquisition, North American and international rights to Telomir-1 were held separately.

The deal provides Telomir with $1.0 million in immediate funding and potential access to an additional $4.0 million through milestone-based contributions from former TELI shareholders. These optional payments are tied to clinical development milestones, including FDA acceptance of an Investigational New Drug application and initiation of a Phase